Zevra Therapeutics Profit Margin

Zevra Therapeutics (KMPH) currently reports a profit margin of 42.82% as of June 2026. That compares with -80.88% in the prior-year period — up 152.9% year over year. That is above the Healthcare sector average of 13.89%. Use the charts on this page to explore Zevra Therapeutics's profit margin history and peer comparisons.

Zevra Therapeutics's profit margin increased from -80.88% to 42.82% — a 152.9% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Zevra Therapeutics's profit margin of 42.82% is higher than the Healthcare sector average of 13.89%. That is roughly 208.2% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Zevra Therapeutics's current 42.82% should be judged against Healthcare norms (sector average: 13.89%) and against KMPH's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 42.82%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for Zevra Therapeutics, and consider following KMPH for alerts when major investors trade the stock.